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Abstract/Summary:  
 
Evaluation of: Ko MA, Zehong G, Virtanen C, et al.. MicroRNA Expression Profiling of 
Esophageal Cancer Before and After Induction Chemoradiotherapy. Ann Thorac Surg. 
94(4),1094-1103 (2012). 
 
Most patients undergoing surgery for esophageal cancer are treated before surgery with 
chemotherapy and radiotherapy. However, some tumors respond poorly to these 
treatments. Ko and colleagues profiled microRNA levels in esophageal cancers from 
patients who did vs. did not respond to chemoradiotherapy. A large number of 
microRNAs were differentially expressed between responders vs. non-responders, and 
patients with either decreased miR-135b or increased miR-145 expression in cancer 
tissue had improved disease free survival. Although this study has several limitations, 
including a mixed cohort of patients with adenocarcinoma and squamous cell carcinoma, 
and the absence of a validation set of patients, the results do suggest that a microRNA 
profiling approach may be able to circumvent one of the primary challenges for 
biomarker development, molecular heterogeneity. 
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Body of the article:  
 
Esophageal cancer is the sixth commonest cause of cancer related death in the Western 
World, and the incidence of esophageal adenocarcinoma (EAC) has increased 6-fold over 
the past 3 decades in the Western World, especially in men, whilst the incidence of 
squamous cell carcinoma (SCC) has essentially remained unchanged. The prognosis for 
both EAC and SCC is poor, with most patients presenting with advanced disease. Hence, 
much research has centered on the development of pre-surgical (neoadjuvant) chemo- or 
chemoradiotherapy regimes, and recent meta-analyses suggest that these approaches 
improve overall survival following surgery for patients with both types of esophageal 
cancer. However, the clinical response to these treatments is variable, with a significant 
proportion of patients responding poorly to chemo- or chemoradiotherapy regimes, either 
in the neoadjuvant, palliative or definitive care settings. Hence, those patients who 
undergo chemo- or chemoradiotherapy, but respond poorly, don’t benefit, and may even 
be harmed by treatment. A biological marker, or more likely a panel of markers, that can 
predict tumor response to chemo- or chemoradiotherapy regimes, might be used to tailor 
treatment to patients for whom chemo- or chemoradiotherapy is likely to be beneficial, 
and to avoid it in those unlikely to benefit. The paper published by Ko et al attempts to 
address this issue, by exploring microRNA expression biomarkers as determinants of 
response. 
 
MicroRNAs inhibit the expression of target genes at the post-transcriptional level, and 
are promising candidates as therapy response biomarkers. Recent studies have suggested 
direct links between miRNAs and the processes leading to cancer, and miRNAs also have 
a role in tumor biology. There is some evidence that their expression correlates with 
treatment outcomes. For example, miR-21 expression correlates with the therapeutic 
outcome in colonic adenocarcinoma [1]. Importantly, there is also evidence that 
modulation of miRNAs can alter tumor cell sensitivity to chemotherapy in vitro [2]. 
 
Methods and results 
Ko et al’s study included 25 patients with clinical stage III adenocarcinoma or squamous 
cell carcinoma of the esophagus who underwent neoadjuvant chemoradiotherapy 
(irinotecan, cisplatin and radiotherapy ) followed by esophagectomy. Pathology 
specimens were reviewed by a single pathologist, and patients were separated according 
to response to therapy. A pathological complete response (pCR) was defined as no viable 
tumor cells remaining in the surgical specimen. 32% of the 25 patients had a pCR, 60% a 
partial response, and 8% no response.  
 
For miRNA biomarker evaluation archived formalin fixed paraffin embedded material 
was obtained pre-treatment by endoscopic biopsy, and post-treatment from the resected 
surgical specimen. RNA was extracted from 10 µm sections, and hybridized to 
microarrays. After samples were ordered into test categories, the data were filtered to 
remove microRNAs that were not above the 20th percentile in more than 50% of samples 
in any single category.  
 
Samples were classified as complete (pCR) vs incomplete (non-pCR) response, and data 
were analyzed via two-way unsupervised hierarchical clustering. In the pCR vs. non-pCR 
clustering, for both pre- vs. post-therapy, miRNA profiling with the complete 1,536 gene 
set was unable to reliably classify pCR vs. non-pCR, although this approach performed 
well in distinguishing pretreatment from post-treatment specimens, with 26 of 27 (96%) 
post-treatment tissues correctly grouped. MiRNA expression differences between groups 
were then subjected to t tests, and supervised clustering analysis was performed using 
miRNAs with p<0.05. For pre-treatment specimens, using 71 differentially expressed 
miRNAs, supervised clustering correctly grouped all patients with a pCR, and correctly 
grouped 13 of the 17 (76%) non-pCR patients. 51 microRNAs were differentially 
expressed in the post-treatment tissues between pCR vs. non-pCR, and in supervised 
clustering 11 of 17 of non-pCR patients were correctly grouped.  
 
Kaplan Meier analysis with log rank tests were used for associations between pCR vs. 
disease free survival, and between specific miRNAs vs. disease free survival. The 
association of pCR vs. disease free survival was not significant, reflecting a small number 
of patients. High miR-145 was associated with increased disease free survival (11.5  vs. 
5.1 months), as was decreased miR-135b (11.5 vs. 2.8 months).  
 
Discussion & significance 
The results of this study suggest that miRNA expression patterns reflect tumour response 
to chemoradiotherapy, raising the possibility of using these biomarkers to tailor treatment 
to patients most likely to benefit. However, there are some methodological issues that 
might limit the reliability of the findings, and further work will be required to take these 
concepts forward. 
 
It must be noted that a standard statistical approach to adjust the false discovery rate of 
the array data was not used.  A two step filtering approach was used instead. While two 
stage filtering approaches have been found to improve detection power over the family-
wise error rate or false discovery rate approaches, it has been suggested that this approach 
can lead to type I errors [3]. 
 
The results of the supervised clustering analyses suggest that miRNA profiling to 
generate response signatures has potential for clinical utility in this context, compared 
with single-biomarker and even multi-biomarker panels which are limited by molecular 
heterogeneity [4]. However, it is possible that these results over-estimate the clinical 
applicability of the profiles, and. it is essential that these results are validated in an 
independent set of tissues that were not used to determine the differentially expressed 
microRNAs.  Also, microarrays are relatively expensive compared with single biomarker 
assays and the data analysis is not trivial, and for this reason more work needs to be done 
to demonstrate cost-effectiveness. 
 
The mixed cohort of patients with adenocarcinoma and squamous cell carcinoma adds 
further complexity. These are histologically different cancers with functionally different 
levels of miRNA expression. For example, Hu et al (2011) reported that miR-16-2, miR-
30e and miR-200a expression were associated with shorter overall and disease-free 
survival in patients with esophageal adenocarcinoma, whereas they did not observe an 
association in esophageal squamous cell carcinomas [5], and Hummel et al (2011) 
reported that expression of miR-21 correlated with lymph node status in esophageal 
squamous cell carcinoma but not in adenocarcinoma [6]. 
 
However, whilst encouraging, the results must be interpreted within the limitations of the 
study. The investigators provide no detail about how they determined expression level 
thresholds for survival analyses, and in future this should be determined via e.g. ROC 
curve analysis of data from a validation set, with the expression levels of specific 
miRNAs measured by an alternative method such as real time PCR. The investigators 
also noted that the results for miR-145 were the opposite of what would be expected 
given this miRNA’s documented role as a tumor suppressor. This incongruent 
observation might be the result of increased stromal involvement in tumor formation (e.g.  
myofibroblasts express high levels of miR-145) [8], and/or the result of transition of 
epithelial cells to mesenchymal cells in the tumors [9].  
 
 
 
Expert commentary and Five-year view 
 
The current study suggests that individual miRNAs may be able to identify patients who 
will have longer disease free survival after neoadjuvant chemoradiotherapy followed by 
surgery. Arguably more importantly,  this study also provides preliminary evidence 
suggesting that profiling of primary tumors with miRNAs microarrays might differentiate 
patients with a complete pathological response to pre-operative chemotherapy from non-
responders. This type of signature profiling approach may have increased clinical utility 
in this context compared with single-biomarkers and even multi-biomarker panels which 
are limited by molecular heterogeneity. Although the mixed cohort of esophageal 
adenocarcinoma and squamous cell carcinoma patients would be expected to  potentially 
confound the results, supervised hierarchical clustering of 71 microRNAs in pre-therapy 
biopsies correctly identified all of the patients with a complete pathological response to 
chemotherapy in the training set. It is therefore important that these results are validated 
in a separate cohort of patients, and further validated with another technology such as 
high throughput real time PCR or deep sequencing. 
 
The investigation of molecular biomarkers for esophageal cancer diagnosis, risk 
stratification, and prognosis has had limited success, and there is accumulating evidence 
that this may in part be due to the heterogeneous nature of these diseases. For example, 
Owonikoko et al (2002) reported inter- and intra-tumoral genetic heterogeneity  of 
various gene amplifications and loss of heterozygosity loci in esophageal 
adenocarcinoma [10], and Merlo et al (2010) observed that increased diversity of 
different molecular clones within Barrett’s esophagus was associated with a high risk of 
progression to esophageal adenocarcinoma [11]. These observations suggest that we may 
have to reconsider the reductionist approach to biomarker screening and development, 
and further investigate the possibility that profiling with relatively large numbers of 
biomarkers may provide greater levels of sensitivity and specificity. A similar conclusion 
was reached by Kihara et al (2001) based on cDNA microarray investigations of the 
outcomes of patients with late stage esophageal squamous cancer after chemotherapy: 
“The usefulness of the prediction of the outcome of adjuvant chemotherapy…raises a 
possibility that extended analyses of expression profiles with an increased number of 
genes using a larger number of samples will help in the development of a more accurate 
classification system.” [12].  
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